Press release - Innophore will receive credits and customized expertise from Amazon Web Service (AWS) to develop a new diagnostic tool to track and monitor SARS-CoV-2 variants using structure models.
Graz, Austria October 10th, 2021 – Innophore, a pioneering bioinformatics company in the field of drug and enzyme discovery, today announced that it has been selected for the Amazon Web Services (AWS) Diagnostic Development Initiative, a global program focused on accelerating research and innovation to advance the collective understanding and detection of COVID-19 and other infectious diseases.
The project targets accelerating the understanding and prediction of SARS-CoV-2 variants to improve awareness and readiness in diagnostics and the development of upcoming medications. Innophore is supported with AWS credits and technical expertise to host Innophore’s innovation in the AWS cloud. Innophore is using Amazon EC2 and S3 for this project that leverage scientific and public SARS-CoV-2 genomic data to generate structural models for predicting future variants of concern in the global AWS cloud.
The giant support from AWS will advance Innophores´s efforts to develop and establish an online platform that can be used by laboratories worldwide to test whether the genetic information in their samples has a mutation that leads to a more dangerous variant. This early diagnosis of variants that have a higher baseline replication number is key to early containment efforts.
“We are excited to receive support from the AWS Diagnostic Development Initiative as we develop and handle robust predictions of SARS-CoV-2 variants,” said Christian Gruber, CEO of Innophore. “We look forward to predicting potentially dangerous or possible new infectious variants with AWS services, which will provide some confidence in handling new variants of the pathogen.”
Proud to be